Measuring the health utility of chronic eustachian tube dysfunction

Abstract

Objective To assess the health utility of chronic Eustachian tube dysfunction (ETD). Methods This is a prospective study of 53 patients with chronic ETD recruited from a tertiary clinic from April 2017 to July 2018. The 7‐Item Eustachian Tube Dysfunction Questionnaire (ETDQ‐7) was administered, and health utility was evaluated using the EuroQol‐5 Dimensions‐3 Level Instrument (EQ‐5D‐3L), the visual analogue scale (VAS), time tradeoff (TTO), and standard gamble (SG). Participants were grouped into medical or procedural management groups. One‐week follow‐up included repeated health utility measures and ETDQ‐7. Results Fifty‐three patients were included in the final analysis. Of those, 34 were managed medically, and 19 received myringotomies ± PE tubes. The mean baseline ETDQ‐7 was 4.26 ± 1.31; whereas health utility measures were different depending on the method utilized: EQ‐5D‐3L 0.90 ± 0.11; VAS 0.76 ± 0.21; TTO 0.85 ± 0.23; and SG 0.94 ± 0.11 (P < .001). There was a significant change in ETDQ‐7 (P = .001) and TTO (P = .011) scores posttreatment. On the ETDQ‐7, question 2 (pain in the ears) was significantly associated with VAS (P = .032), and question 4 (ear symptoms during a cold or sinusitis) was significantly associated with TTO (P = .006). Conclusion Chronic ETD has a significant burden on quality of life, with a health utility similar to gastroesophageal reflux disease and moderate asthma. Although treatment‐related changes are measurable using disease‐specific quality‐of‐life measures, only TTO was significantly changed after treatment. Health utility seemed to depend on the method of measurement but provided a benchmark for evaluating cost‐effectiveness of innovations to manage ETD. Level of Evidence 2 Laryngoscope, 130:E39–E44, 2020

Effect of nasal fluticasone exhalation delivery system on Eustachian tube dysfunction

“…Chronic ETD is common and causes a significant burden on quality of life, 9,10 but there are few effective treatments for this condition. The only study evaluating INCS for chronic ETD did not find any benefit over placebo, yet these medications are still routinely used 2 .…”

Health States Utility Value in COVID-19

“…COVID-19 disease in terms of a detrimental effect on HRQoL among survivors of diseases is comparable with Crohn's disease, ulcerative colitis [26], thalassemia patients that receive oral iron chelator [27], rheumatoid arthritis [28] and chronic eustachian Tube dysfunction [29]. All of these diseases lead to the loss of 15-17% of patients' HRQoL.…”

Tubomanometry correlations with patient characteristics and other diagnostic tests of Eustachian tube dysfunction: a cohort study of 432 ears

“…The prevalence of obstructive Eustachian tube dysfunction (OETD) in adults is estimated to be 5% [ 2 ]. ETD symptoms such as otalgia, a feeling of pressure, and hearing impairment decrease patients’ quality of life [ 3 ]. Chronic OETD can lead to several middle ear pathologies, such as atelectasis of the tympanic membrane (TM), otitis media with effusion, and cholesteatoma [ 4 ].…”